Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study

Purpose Aspirin (acetylsalicylic acid) has been reported to protect against certain cancers. However, patient-related risk factors may moderate protective effects, including excess weight, smoking, risky alcohol use, and diabetes. We explore the cancer-risk relationship between aspirin intake and th...

Full description

Bibliographic Details
Authors: Florensa Cazorla, Dídac, Mateo Fornés, Jordi, Solsona Tehàs, Francesc, Galván, Leonardo, Mesas, Miquel, Piñol, Ramon, Espinosa-Leal, Leonardo, Godoy i García, Pere
Format: article
Status:Published version
Publication Date:2023
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/463602
Online Access:https://doi.org/10.1016/j.annepidem.2023.06.002
https://hdl.handle.net/10459.1/463602
Access Level:Open access
Keyword:Aspirin
Acetylsalicylic acid
Risk factor
Lifestyle
Comorbidity
Cancer
Retrospective cohort study
id ES_dcf8e8df8003fea9ce38290fd3cfe693
oai_identifier_str oai:recercat.cat:10459.1/463602
network_acronym_str ES
network_name_str España
repository_id_str
spelling Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort studyFlorensa Cazorla, DídacMateo Fornés, JordiSolsona Tehàs, FrancescGalván, LeonardoMesas, MiquelPiñol, RamonEspinosa-Leal, LeonardoGodoy i García, PereAspirinAcetylsalicylic acidRisk factorLifestyleComorbidityCancerRetrospective cohort studyPurpose Aspirin (acetylsalicylic acid) has been reported to protect against certain cancers. However, patient-related risk factors may moderate protective effects, including excess weight, smoking, risky alcohol use, and diabetes. We explore the cancer-risk relationship between aspirin intake and those four factors. Methods Retrospective cohort study of cancers, aspirin intake, and four risk factors in persons aged ≥50 years. Participants received medication during 2007–2016, and cancers were diagnosed in 2012–2016. Adjusted hazard ratios (aHR) for 95% confidence intervals (95%CI) were calculated for aspirin intake and risk factors using Cox proportional hazard modeling. Results Of 118,548 participants, 15,793 consumed aspirin, and 4003 had cancer. Results indicated a significant protective effect of aspirin against colorectal (aHR: 0.7; 95%CI: 0.6–0.8), pancreatic (aHR: 0.5; 95%CI: 0.2–0.9), prostate (aHR: 0.6; 95%CI: 0.5–0.7) cancers and lymphomas (aHR: 0.5; 95%CI: 0.2–0.9), and also, although not significantly, against esophageal (aHR: 0.5; 95%CI: 0.2–1.8), stomach (aHR: 0.7; 95%CI: 0.4–1.3), liver (aHR: 0.7; 95%CI: 0.3–1.5), breast (aHR: 0.8; 95%CI: 0.6–1.0), and lung and bronchial (aHR: 0.9; 95%CI: 0.7–1.2) cancers. Aspirin intake was not significantly protective against leukemia (aHR: 1.0; 95%CI: 0.7–1.4) or bladder cancer (aHR: 1.0; 95%CI: 0.8–1.3). Conclusions Our results suggest that aspirin intake is associated with a reduced incidence of colorectal, pancreatic, and prostate cancers and lymphomas.This work was supported by contract 2019-DI-43 of the Industrial Doctorate Programme of the Generalitat de Catalunya (Project PID2020-113614RB-C22 funded by MCIN/AEI/10.13039/ 501100011033). Some authors are members of the 2014-SGR163 research group, funded by the Generalitat de Catalunya. The author wishes to thank Arnau de Vilanova University Hospital, Santa Maria University Hospital, and the Catalan Health Service (CatSalut) in Lleida for research support and resources. The authors also acknowledge CSC – IT Center for Science in Finland for computing resourcesElsevier2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1016/j.annepidem.2023.06.002https://hdl.handle.net/10459.1/463602reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Inglésinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-113614RB-C22Reproducció del document publicat a https://doi.org/10.1016/j.annepidem.2023.06.002Annals of Epidemiology, 2023, vol. 84, p. 60-66cc-by (c) Dídac Florensa et al., 2023Attribution 4.0 Internationalinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:recercat.cat:10459.1/4636022026-05-29T05:05:01Z
dc.title.none.fl_str_mv Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
title Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
spellingShingle Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
Florensa Cazorla, Dídac
Aspirin
Acetylsalicylic acid
Risk factor
Lifestyle
Comorbidity
Cancer
Retrospective cohort study
title_short Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
title_full Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
title_fullStr Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
title_full_unstemmed Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
title_sort Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
dc.creator.none.fl_str_mv Florensa Cazorla, Dídac
Mateo Fornés, Jordi
Solsona Tehàs, Francesc
Galván, Leonardo
Mesas, Miquel
Piñol, Ramon
Espinosa-Leal, Leonardo
Godoy i García, Pere
author Florensa Cazorla, Dídac
author_facet Florensa Cazorla, Dídac
Mateo Fornés, Jordi
Solsona Tehàs, Francesc
Galván, Leonardo
Mesas, Miquel
Piñol, Ramon
Espinosa-Leal, Leonardo
Godoy i García, Pere
author_role author
author2 Mateo Fornés, Jordi
Solsona Tehàs, Francesc
Galván, Leonardo
Mesas, Miquel
Piñol, Ramon
Espinosa-Leal, Leonardo
Godoy i García, Pere
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Aspirin
Acetylsalicylic acid
Risk factor
Lifestyle
Comorbidity
Cancer
Retrospective cohort study
topic Aspirin
Acetylsalicylic acid
Risk factor
Lifestyle
Comorbidity
Cancer
Retrospective cohort study
description Purpose Aspirin (acetylsalicylic acid) has been reported to protect against certain cancers. However, patient-related risk factors may moderate protective effects, including excess weight, smoking, risky alcohol use, and diabetes. We explore the cancer-risk relationship between aspirin intake and those four factors. Methods Retrospective cohort study of cancers, aspirin intake, and four risk factors in persons aged ≥50 years. Participants received medication during 2007–2016, and cancers were diagnosed in 2012–2016. Adjusted hazard ratios (aHR) for 95% confidence intervals (95%CI) were calculated for aspirin intake and risk factors using Cox proportional hazard modeling. Results Of 118,548 participants, 15,793 consumed aspirin, and 4003 had cancer. Results indicated a significant protective effect of aspirin against colorectal (aHR: 0.7; 95%CI: 0.6–0.8), pancreatic (aHR: 0.5; 95%CI: 0.2–0.9), prostate (aHR: 0.6; 95%CI: 0.5–0.7) cancers and lymphomas (aHR: 0.5; 95%CI: 0.2–0.9), and also, although not significantly, against esophageal (aHR: 0.5; 95%CI: 0.2–1.8), stomach (aHR: 0.7; 95%CI: 0.4–1.3), liver (aHR: 0.7; 95%CI: 0.3–1.5), breast (aHR: 0.8; 95%CI: 0.6–1.0), and lung and bronchial (aHR: 0.9; 95%CI: 0.7–1.2) cancers. Aspirin intake was not significantly protective against leukemia (aHR: 1.0; 95%CI: 0.7–1.4) or bladder cancer (aHR: 1.0; 95%CI: 0.8–1.3). Conclusions Our results suggest that aspirin intake is associated with a reduced incidence of colorectal, pancreatic, and prostate cancers and lymphomas.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1016/j.annepidem.2023.06.002
https://hdl.handle.net/10459.1/463602
url https://doi.org/10.1016/j.annepidem.2023.06.002
https://hdl.handle.net/10459.1/463602
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-113614RB-C22
Reproducció del document publicat a https://doi.org/10.1016/j.annepidem.2023.06.002
Annals of Epidemiology, 2023, vol. 84, p. 60-66
dc.rights.none.fl_str_mv cc-by (c) Dídac Florensa et al., 2023
Attribution 4.0 International
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c) Dídac Florensa et al., 2023
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421817661227008
score 15.811543

Similar Items